HCPCS Level II code Q4101 denotes Apligraf billed per square centimeter as an add-on product used in the management of wounds requiring a biologic skin substitute. Nationally, the code matters because it standardizes reporting for a costly, product-based intervention that is used across outpatient wound care, surgical, and dermatologic settings. Proper use of the code affects coverage determinations and claim adjudication for a specialty supply applied in addition to primary procedures.

Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for Apligraf use, typical sites of service where the product is applied, and the implications for billing as an add-on supply. The publication provides benchmarks for utilization and reimbursement patterns, summarizes relevant policy updates that influence coverage decisions, and outlines documentation and coding considerations tied to the add-on nature of the product.

This resource is intended for billing specialists, revenue cycle leaders, and clinicians involved with wound care to clarify what Q4101 represents, where it is commonly used, and what topics to review when managing claims for biologic skin substitute products.